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uphs.uAbstract—The literature describing the use of low-intensity ultrasound in four major areas of cancer therapy—
sonodynamic therapy, ultrasound-mediated chemotherapy, ultrasound-mediated gene delivery and anti-vascular
ultrasound therapy—was reviewed. Each technique consistently resulted in the death of cancer cells, and the bio-
effects of ultrasound were attributed primarily to thermal actions and inertial cavitation. In each therapeutic
modality, theranostic contrast agents composed of microbubbles played a role in both therapy and vascular imag-
ing. The development of these agents is important as it establishes a therapeutic–diagnostic platform that can
monitor the success of anti-cancer therapy. Little attention, however, has been given either to the direct assessment
of the mechanisms underlying the observed bio-effects or to the viability of these therapies in naturally occurring
cancers in largermammals; if such investigations provided encouraging data, there could be prompt application of
a therapy technique in the treatment of cancer patients. (E-mail: Sehgalc@uphs.upenn.edu)  2015 World
Federation for Ultrasound in Medicine & Biology.
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Low-intensity ultrasound has been used in a variety of
therapeutic applications. Together with sensitizing mole-
cules it has been used to affect cancer cells (sonodynamic
therapy); it has enhanced the activity of chemotherapeutic
molecules in cancer therapy (ultrasound-mediated che-
motherapy); it has been used to affect cells and their com-
ponents directly (sonoporation); it has been used for gene
delivery or transfection and to promote bone and tissue
heating/healing and for its anti-vascular actions on tumor
neovasculature. This appraisal of the literature focuses on
the role of low-intensity ultrasound in cancer therapy. The
published studies have included in vitro observations of
cancer cell suspensions and cultures and the treatment
of an extensive range of implanted tumors in small
laboratory animals. This review covers four of the major
areas in which low-intensity ultrasound has been used for
cancer therapy studies: sonodynamic therapy, ultrasound-
mediated chemotherapy, ultrasound-mediated gene deliv-
ery and anti-vascular ultrasound therapy.ddress correspondence to: Chandra M. Sehgal, PhD, Professor,
ment of Radiology, University of Pennsylvania Medical Center,
pruce Street, Philadelphia, PA 19104, USA. E-mail: Sehgalc@
penn.edu
905To date there is no widely accepted definition of
low-intensity ultrasound, but this review has centered
on investigations in which cancer cells or tumors have
generally been insonated with an intensity less than 5.0
W cm22, corresponding to a root-mean-square pressure
amplitude of about 0.3 MPa. Many variable sonication
conditions have been used for the studies in the literature,
making it difficult to make accurate comparisons between
the reports. To aid the comparisons in this review, pres-
sure–intensity conversions were made using the formula
I 5 p2/rc, where I 5 intensity, p 5 root mean square
pressure amplitude, r 5 density and c 5 sound speed
(Preston 1991).
In general terms, insonation of neoplasms with
low-intensity ultrasound is easy to perform as it does
not require a focused beam (that must be accurately
located), the apparatus is relatively inexpensive, the
bio-effects in adjacent normal tissues are commonly
believed to be minimal and it is possible to easily target
sensitizing or chemotherapeutic molecules and micro-
bubbles located within the lumens of the tumor neovas-
culature. Treatment times are, however, prolonged in
comparison to those used in high-intensity focused
ultrasound, but repeated treatments or dose fractionation
is easily performed.
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The term sonodynamic therapy derives from photo-
dynamic therapy. However, unlike photodynamic ther-
apy, in which photosensitizers are excited directly by
light to produce reactive oxygen species, sonodynamic
therapy is mediated via ultrasound-induced cavitation
and sonosensitizers to produce free radicals that kill
nearby rapidly dividing cancer cells (Fig. 1). An attrac-
tion of sonodynamic therapy, in which continuous, low-
intensity ultrasound at diagnostic ultrasound frequencies
is used, is its ability to treat deeply located tumors. On
the other hand, photodynamic therapy uses visible light,
which attenuates rapidly in tissues, has limited penetra-
tion and can be employed only superficially or intra-
operatively. When comparing the efficacy of the two
methods, Jin et al. (2000) treated a subcutaneously located
murine squamous cell carcinoma and found that sonody-
namic therapy inhibited tumor growth by 77%, compared
with 27% for photodynamic therapy. The latter was not
as effective a therapy in the deeper regions of the tumor.
Sonodynamic therapy initially used the same light-
sensitive agents, hematoporphyrin and its derivatives,
that had been developed for photodynamic therapy. An
ideal sensitizing agent should be preferentially taken up
and retained in the tumor so that the therapy damages
cancer cells, but has minimal bio-effects in the surround-
ing normal tissues; the agent should also be relatively
non-toxic to normal mammalian tissues. To improve
the efficacy of treating solid tumors, it is important that
the sonosensitizer is injected intravenously before
insonation, rather than directly into the tumor, so that
it is more fully and evenly distributed throughout the
neoplasm (Ninomiya et al. 2012).
Overviews of the sonosensitizers used in the
therapy have been published (Chen et al. 2014; Feril
et al. 2011; Kuroki et al. 2007; Shibaguchi et al. 2011).
In sonodynamic therapy, the sonication parameters
(usually 1.0–2.0 MHz at an intensity of 0.5 to 3.0 W
cm22) (Tables 1 and 2) have been selected to produce
inertial cavitation in a cell culture or tumor, where
microbubbles rapidly collapse resulting in shockwavesFig. 1. Schema of sonodynamic therapy. Low-intensity inson
causes cavitation, leading to the production of free radicalthat produce free radicals and a cascade of molecular
events that activate the sonosensitizer and, in turn,
damage the cancer cells (Misik and Riesz 2000;
Rosenthal et al. 2004; Yu et al. 2004c). Although
the production of reactive oxygen species appears
important in the anti-tumor affect, Wang et al. (2011a)
stated that thermal effects cannot be excluded. In addition
to these direct cytotoxic effects on neoplastic cells, it is
also important to consider other possible effects on the
growing tumor, including its vascular supply. Gao et al.
(2013) reported that sonodynamic therapy also has an
anti-vascular effect and inhibits tumor neovascularization.
Another approach has been to use a chemotherapeutic
agent as the sonosensitizer. In in vitro studies of adria-
mycin (Gao et al. 2010), cisplatin (Bernard et al. 2011,
2012 [0.4 6 0.02 MPa]) and doxorubicin (Liang et al.
2013), it was found that these agents were cytostatic, and
apoptosis was further enhanced when they were used in
combination with chlorine e6 (Gao et al. 2010) or a
hematoporphyrin (Liang et al. 2013).
After the initial descriptions of sonodynamic therapy
by Yumita et al. (1989) and Umemura et al. (1990), there
were numerous confirming reports that further revealed
the bio-effects of the therapy. In contrast to the earlier re-
views, we have grouped the research studies according to
the type of cancer cell and accompanying sonosensitizer
that were insonated; the aimwas to provide a guide to pre-
vious sonodynamic studies in which the type of cancer
receiving therapy is emphasized (Tables 1 and 2).
Considerable data have been published over the past 25
y using many different sonosensitizers and involving
many types of cancer (Tables 1 and 2), and each report
has consistently indicated the significant bio-effects of
sonodynamic therapy. The relative merits of each of these
numerous sonodynamic agents are, however, difficult to
determine as each of the agents was investigated in isola-
tion without comparing the efficacy of one against
another. Thus, key questions remain to be answered, for
example: Are the recently developed nanoparticle sono-
sensitizers anymore effective than the original porphyrins
in killing cancer cells?ation of cancer cells in the presence of a sonosensitizer
s with resultant cell death by apoptosis and necrosis.
Table 1. Sonodynamic therapy of cell cultures and suspensions
Cancer cell culture/suspension Sonosensitizer
Insonation parameters
ReferenceMHz W cm22
i. Murine sarcoma 180 Hematoporphyrin 1.92 1.27–3.18 Yumita et al. 1989
Hematoporphyrin 1.9 1.8 Umemura et al. 1990
Hematoporphyrin 1.75 1.4 Tang et al. 2008a, 2008b
Hematoporphyrin 1.8 2.1 Tang et al. 2008c
Hematoporphyrin 1.6 1.0–6.0 Wang et al. 2008a
Pheobromide-a 1.92 4.5 Umemura et al. 1996a
ATX-S10 1.92 4.5 Yumita et al. 2000a
Photofrin II 1.93 5.9 Yumita et al. 2000c
Protoporphyrin IX 1.0 5.0 Umemura et al. 1996b
Protoporphyrin IX 2.2 1.0–7.0 Liu et al. 2006a
Protoporphyrin IX 2.2 3.0 Wang et al. 2008c
Protoporphyrin IX 2.2 3.0 Wang et al. 2008b
Protoporphyrin IX 1.1 0.64–2.1 Wang et al. 2010
Rose Bengal derivative 1.92 2.0–8.0 Sugita et al. 2010
DCPH–P–Na(I) 2.0 5.9 Yumita et al. 2010
NPe6 1.92 4.5 Yumita et al. 2011
Polyhydroxy fullerenes 1.92 4.5 Yumita et al. 2013
ii. Hepatic Hematoporphyrin 1.92 1.27–3.18 Yumita et al. 1989
Hematoporphyrin 1.43 1.0–4.0 Liu et al. 2008b
Titanium nanoparticles 1.0 0.1 Ninomiya et al. 2012
Titanium nanoparticles 0.5, 1.0 0.8, 0.4 Ninomiya et al. 2014
Hypocrellin-B 1.7 0.46 Wang et al. 2012b
iii. Nasopharyngeal Curcumin 1.7 0.46 Wang et al. 2011b
Curcumin 1.7 0.46 Wang et al. 2011c
Curcumin 1.7 0.46 Wang et al. 2012c
iv. Glioma ZnPcS2 P2 1.0 0.5 Chen et al. 2012b
HMME 1.0 0.5 Li et al. 2013
Photofrin 1.0 0.5 Xu et al. 2012
Photofrin 1.0 0.5 Xu et al. 2013
Titanium nanoparticles 1.0 1.0 Yamaguchi et al. 2011b
v. Human breast Protoporphyrin IX 1.1 1.0 Li et al. 2012b
Chlorin e6 1.0 0.36, 0.72 Wang et al. 2013b
Chlorin e6 1 adriamycin 1.0 0.5–2.0 Gao et al. 2010
vi. Ovarian Cisplatin 1.0 2.0 Bernard et al. 2011
Methylene blue 1.7 0.46 Xiang et al. 2011
vii. Other
Acute myeloid leukemia Chlorine e6 1.1 1.0 Su et al. 2013b
Cholangiocarcinoma Hematoporphyrin 1 doxorubicin 1.2 0.5–2.0 Liang et al. 2013
Ehrlich ascites Protoporphyrin IX 1.34 1.0-5.0 Zhao et al. 2009
Gastric Antibody/porphyrin 1.0 1.0 Abe et al. 2002
Human leukemia Protoporphyrin IX 1.1 1.0 Su et al. 2014
Human melanoma Cisplatin 1.0 1.0 Bernard et al. 2012
Histiocytic lymphoma Hematoporphyrin 1.1 1.0 Su et al. 2013a
Murine leukemia Protoporphyrin IX 1.1 0.64–2.1 Wang et al. 2013c
Murine mammary Chlorine e6 1.0 0.36, 0.72 Li et al. 2013
Tongue 5-Aminolevulinic acid 1.0 0.6, 0.8 Lv et al. 2012
Multiple cell lines Porphyrin derivative 1.0 1.0 Tsuru et al. 2012
1.0 0.5–2.0 Hachimine et al. 2007
viii. Non-neoplastic (endothelial cells) 5-Aminolevulinic acid 1.0 1.0 Gao et al. 2013
ATX-S105 4-formyloximethylidene-3-hydroxy-2-vinyl-deuterio-porphynyl(IX)-6,7-diaspartic acid; DCPH–P–Na(I)5 13,17-bis(1-carboxyethyl)-
8-[2-(2,4-dichlorophenyl-hydrazono)ethylidene]-3-ethenyl-7-hydroxy-2,7,12,18-tetramethylchlorin; Pe6 5 mono-l-aspartyl chlorin e6; HMME 5
hematoporphyrin monomethyl ether.
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ptosis in cancer cell suspensions and cultures and
inhibited tumor growth in animal models of cancer. The
therapy’s effectiveness has also been reported in more
deeply located tumors, including those of the central ner-
vous system (Gao et al. 2013; Jeong et al. 2012; Ohmura
et al. 2011). Post-therapy histologic studies have consis-
tently indicated damage to the ultrastructure of the cancer
cells, including destruction of cell membranes, mitochon-drial swelling and chromatin condensation (Liu et al.
2006a, 2007a, 2007b, 2008a; Wang et al. 2008a, 2011c,
2012c); it was considered that these changes induced by
the therapy may have mediated cancer cell death.
Combining photodynamic therapy with sonodynamic
therapy had a synergistic effect in solid tumors with
additional post-therapy tumor necrosis, inhibition of
tumor growth and increased survival times (Jin et al.
2000; Tserkovsky et al. 2012).
Table 2. Sonodynamic therapy of tumors*
Tumor Sonosensitizer
Insonation parameter
ReferenceMHz W cm22
i. Murine sarcoma 180 Hematoporphyrin 1.92 1.7 Yumita et al. 1990
Pheobromide-a 1.92 3.0 Umemura et al. 1996a
Protoporphyrin IX 2.2 5.0 Liu et al. 2007a, 2007b
Sinoporphyrin sodium 1.9 2.0–6.0 Li et al. 2013
ii. Colon ATX-S10 2.0 3.0 Yumita et al. 2000a
Photofrin II 1.92 1.0–5.0 Yumita et al. 2000b
Protoporphyrin IX/nanoparticles 1.1 2.0 Sazgarnia et al. 2011
Protoporphyrin IX/nanoparticles 1.1 2.0 Shanei et al. 2012
NPe6 2.0 3.0 Yumita et al. 2011
Polyhydroxy fullerenes 2.0 3.0 Yumita et al. 2013
iii. Hepatic Hematoporphyrin 1.43 2.0 Liu et al. 2008b
Protoporphyrin IX 1.43 3.0 Wang et al. 2011a
Titanium oxide nanoparticles 1.0 1.0 Ninomiya et al. 2012
Hematoporphyrin microbubbles 1.0 2.0 Zheng et al. 2012
Chlorin e6 1.56 4.0 Shi et al. 2011
iv. Glioma (rats) 5-Aminolevulinic acid 1.04 10.0 Ohmura et al. 2011
5-Aminolevulinic acid 1.0 2.65 Jeong et al. 2012
Chlorin e6/polyvinyl pyrrolidone 1.0 0.4–1.0 Tserkovsky et al. 2012
v. Breast Photofrin 0.015/1.0 0.2, 2.0 Barati and Mokhtari-Dizaji 2010
No sensitizer 0.015/1.0 0.2, 2.0 Barati et al. 2009
vi. Gastric Antibody/gallium–porphyrin 1.0 2.0 Abe et al. 2002
Porphyrin derivative 1.0 2.0 Tsuru et al. 2012
vii. Other Squamous cell Gallium–porphyrin/pheophorbide-a 1.0 0.51 Jin et al. 2000
Osteosarcoma (rats) Hematoporphyrin 10.5 0.8 Tian et al. 2009
Small cell lung Chlorin e6 1.0 0.4–1.6 Chen et al. 2013a
Tongue 5-Aminolevulinic acid 1.1 2.0 Gao et al. 2013
Human MKN-45 DCPH–P–Na(I) 1.0 2.0 Hachimine et al. 2007
ATX-S10 5 4-formyloximethylidene-3-hydroxy-2-vinyl-deuterio-porphynyl(IX)-6,7-diaspartic acid; NPe6 5 mono-l-aspartyl chlorin e6.
* Unless otherwise stated all tumors were in mice.
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tizers (Tables 1 and 2) were initially developed for use
in photodynamic therapy, it is important that those used
in the future for sonodynamic therapy should have low
or no sensitivity to light and cause minimal cutaneous
side effects (Gao et al. 2013; Ninomiya et al. 2012;
Shibaguchi et al. 2011; Tsuru et al. 2012). Preliminary
data from solid tumors support the administration of a
regimen of multiple therapies to further enhance the
bio-effects and so reduce tumor growth and size; fraction-
ation will also reduce the thermal effects of therapy
(Jeong et al. 2012).
Combination of the sonosensitizer with a microbub-
ble contrast agent may lead to important future develop-
ments in sonodynamic therapy (Zheng et al. 2012). The
combined agent can then be classified as a theranostic
agent as the entry of the loaded microbubbles into the
tumor vasculature can be monitored by ultrasound imag-
ing, and once it is detected within the tumor by diagnostic
ultrasound, sonodynamic therapy can be initiated. A
therapeutic–diagnostic platform is established that can
monitor the efficacy of therapy (Lionetti and Paddeu
2010). Further, insonation of the microbubble may lead
to additional significant local thermal bio-effects
with destruction of the endothelial cells lining thetumor vasculature and a decrease in tumor vascularity
(Levenback et al. 2012).
To date, the in vivo observations have been per-
formed in implanted subcutaneous tumors of laboratory
animals (mice and rats) so that there remains a need for
future studies in a larger mammal, perhaps using sonody-
namic therapy for treating naturally occurring cancers. If
successful, these additional studies could lead to initial
human clinical trials.ULTRASOUND-MEDIATED CHEMOTHERAPY
In cancer therapy, there is interest in using low-
intensity ultrasound to enhance the delivery of chemo-
therapeutic agents to a solid tumor (Fig. 2, Table 3).
The agents may be non-specific in that they do not selec-
tively target neoplastic cells, and thus, high levels of the
cytotoxic drug will also be present in normal tissues
with possible adverse side effects (Nomikou et al.
2010). Further, factors including poor vascularity and
defective lymphatic drainage can result in high interstitial
fluid pressure within the tumor and prevent the uptake of
therapeutic levels of the drug into the tumor (Nomikou
et al. 2010). Insonation of a tumor in the presence of
the chemotherapeutic agent provides the potential for
Fig. 2. Outline of different approaches to ultrasound-mediated
chemotherapy. Through use of a variety of techniques, low-
intensity ultrasound enhances the delivery of chemotherapeutic
agents to cancer cells. chemo5 chemotherapeutic agent; US5
ultrasound; m-bubbles 5 microbubbles.
Low-intensity US for cancer therapy d A. K. W. WOOD and C. M. SEHGAL 909enhancing delivery of the agent to the cancer cells while
minimizing the cytotoxic effects in contiguous normal
tissues. The delivery of chemotherapeutic agents has
been studied in combination with ultrasound alone,
with ultrasound and microbubbles and with drug-loaded
microbubbles. Additional chemotherapeutic investiga-
tions have been made following insonation of drug-
loaded liposomes in the presence of microbubbles and ul-
trasound and insonation of drug-loaded liposomes
attached to microbubbles (Table 3). In addition to the
role of microbubbles in the delivery of chemotherapy
via these direct effects, other effects related to anti-
vascular activity have also been described and are dis-
cussed later (see Anti-vascular Ultrasound). Also, mag-
netic microbubbles have been developed in which the
drug and iron oxide are co-encapsulated into a microbub-
ble that can be imaged by both ultrasound and magnetic
resonance (MR) imaging. This review has centered on
the results of recently published research studies; for a
general overview of the topic, the reader is referred to ar-
ticles by Nomikou and McHale (2010) and Trendowski
(2014).
Chemotherapy in the presence of ultrasound
The potential for low-intensity ultrasound to increase
the sensitivity of cancer cells to a chemotherapeutic agent
has been investigated both in vitro and in vivo.
In vitro studies. Insonation of tumor cell suspensions
and cultures in the presence of a chemotherapeutic agent
can facilitate the cellular uptake of the agent; the inertial
cavitation induced by the ultrasound beam leads to the
formation of microjets that carry the agent directly into
the cell or disrupt the cell membranes, permitting
the inflow of extracellularly located agents (Feril and
Tachibana 2012).Yoshida et al. (2008) reported, in human myelomo-
nocytic cells, a synergistic enhancement of cell killing
and increased apoptosis when the cells were insonated
in the presence of doxorubicin. Only a few studies have
evaluated the differences in response between chemosen-
sitive and chemoresistant cancer cells. Yu et al. (2004a)
insonated Adriamycin- and cisplatin-resistant substrains
of human ovarian cancer cell lines. They observed
differing bio-effects between chemosensitive and chemo-
resistive cells. Cell proliferation and clone formation in
the chemoresistive cell populations were suppressed by
ultrasound, whereas the chemosensitive cells were unaf-
fected. In another study of doxorubicin, Hassan et al.
(2012) studied human uterine carcinoma cells and a
multidrug-resistant phenotype. The order of application
of insonation and doxorubicin resulted in differences in
the sensitivity of the carcinoma cells. The authors
observed that either the parent carcinoma cells could be
desensitized or the resistant cell could be sensitized to
doxorubicin depending on the time of sonication. Insona-
tion of human tongue carcinoma cells in the presence of
scutellarin significantly enhanced cell injury, with irregu-
larly shaped and fractured microvilli and formation of
apoptotic bodies on scanning electron microscopy; inhi-
bition of cancer cell growth and induction of cell
apoptosis occurred (Li et al. 2013).
In vivo studies. The efficacy of chemotherapy and
ultrasound has also been studied in mouse tumor models.
In a murine lymphoma, Tomizawa et al. (2001) found that
the combination of intraperitoneal bleomycin and ultra-
sound leads to suppression of tumor growth. When camp-
tothecin was injected directly into a fibrosarcoma that
was then insonated, it was hypothesized that the resultant
decrease in tumor growth may have followed the
ultrasound-mediated dispersion of the chemotherapeutic
drug throughout the tumor, including the more poorly
vascularized regions (Nomikou et al. 2010). Chemosensi-
tive and chemoresistant ovarian cancers, implanted in the
murine kidney, were insonated 15 min after the intraper-
itoneal injection of adriamycin (Yu et al. 2004b). Ultra-
sound potentiated the efficacy of adriamycin in both
types of cancer, and thus, it was suggested that ultrasound
reversed the adriamycin resistance in ovarian cancer
cells. In studies of a human tongue squamous cell carci-
noma, scutellarin was orally administered before tumor
insonation, and the combined therapy resulted in inhibi-
tion of tumor growth, angiogenesis and lymphangiogen-
esis (Li et al. 2013).Chemotherapy in the presence of microbubbles and
ultrasound
Chemotherapy in the presence of microbubbles and
ultrasound has the potential to enhance the in vivo
Table 3. Ultrasound-mediated chemotherapy
In vitro/in vivo
Insonation parameter
ReferenceMHz W cm22 PW/CW MPa
Chemotherapy 1 US
In vitro 0.24 5.76 CW Yu et al. 2004a
1.0 0.2–0.5 PW — Yoshida et al. 2008
1.0 0.2–0.5 PW — Hassan et al. 2012
1.0 0.05 PW — Li et al. 2013
In vivo 1.0 2.0 CW — Tomizawa et al. 2001
0.24 7.84 CW — Yu et al 2004 b
1.0 1.0 PW — Nomikou et al. 2010
1.0 0.01–0.12 PW — Li et al. 2013
Chemotherapy in the presence of microbubbles 1 US
In vitro 1.0 0.5–1.0 PW — Watanabe et al. 2008
1.0 — — 0.4–0.8 Escoffre et al. 2011
1.0 — PW 0.5 Heath et al. 2012
0.5–2.25 — PW — Sorace et al. 2012
1.1 2.0–4.0 CW Yang et al. 2014
In vivo 1.0 3.0 PW — Watanabe et al. 2008
1.0 3.0 cont — Lu et al. 2011
1.011 0.64 PW Matsuo et al. 2011
1.0 — PW 0.5 Heath et al. 2012
1.0 — PW 0.1–2.0 Sorace et al. 2012
Chemotherapy-loaded microbubbles 1 US
In vitro 3.0 3.0 PW — Chumakova et al. 2006
1.0 1.0 PW — Tinkov et al. 2010b
1.0 1.0 PW — Yan et al. 2011
5.0 — PW 0.45 Cochran et al. 2011
0.8 2.56 PW — Ren et al 2013
In vivo 1.3 — PW 1.2 Tinkov et al. 2010a
0.3 2.0 PW — Kang et al. 2010
5.0 — PW — Cochran et al. 2011
1.0 2.0 PW — Li et al. 2012c
1.0 — PW 0.7 Ting et al. 2012
Chemotherapy-loaded micelles/liposomes 1 US
In vivo 1.0 3.4 PW — Gao et al. 2005
1.0 3.4 CW — Rapoport et al. 2009
0.029 5.9 CW — Schroeder et al. 2009a
0.02 1.0 CW 0.173 Staples et al. 2010
2.25 — PW 1.9 Yan et al. 2013
Chemotherapy-loaded liposomes in presence of microbubbles 1 US
In vivo 1.0 — — 1.2 Lin et al. 2012a
1.0 0.3 PW Zhao et al. 2012
Chemotherapy-loaded liposomes attached to microbubbles 1 US
In vitro 1.0 2.0 PW — Lentacker et al. 2010
1.0 2.0 PW — Geers et al. 2011
1.0 — — 0.2–0.6 Escoffre et al. 2013
In vivo 3.0 2.0 PW — Rapoport et al. 2007
Chemotherapy and magnetic nanoparticles co-encapsulated onto microbubbles 1 US
In vivo 0.3 2.0 PW — Niu et al. 2013
CW 5 continuous wave; PW 5 pulsed wave; US 5 ultrasound; — 5 parameter not available.
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harmful systemic side effects in normal tissues (Heath
et al. 2012). Watanabe et al. (2008) observed that the
chemo-effect of cisplatin was enhanced in the presence
of ultrasound. They believed that at low intensities, the
enhanced anti-tumor effect of the chemotherapeutic
agent was associated with cavitating microbubbles. At
very low intensities, however, it remains to be learned
whether the microbubbles collapse or simply undergo
volume oscillations. The pressures thus generated caused
transient increases in the permeability of cell membranes,allowing exogenous molecules such as chemotherapeutic
agents to enter the cell. Further, the intracellular delivery
of therapeutic compounds may be facilitated by endocy-
tosis and pore formation involving the endothelial cells
lining blood vessels. Meijering et al. (2009) reported
that, after insonation (1.0 MHz, 0.22 MPa) of normal
rat femoral arteries in the presence of circulating micro-
bubbles, dextran molecules became localized in intracel-
lular vesicles, indicating uptake of macromolecules by
endocytosis. Also, endothelial cell pore formation was
demonstrated by influx of calcium ions and cellular
Low-intensity US for cancer therapy d A. K. W. WOOD and C. M. SEHGAL 911release of dextrans. In an in vitro study using ultrasound
alone (1.5 MHz, 0.3 W cm22, 0.07 MPa), it was also
found that endocytotic vesicles and clathrin (a protein
that plays a major role in the formation of coated vesicles)
coated pits formed in fibroblasts (Hauser et al. 2009) and
again provided ameans for the uptake of drugs in addition
to sonoporation.
It should also be noted that the release of the chemo-
therapeutic agent from intravascular microbubbles will
also affect the blood vessels, killing the vessels and
permitting the therapeutic agent to leave the vessel. The
direct effects of microbubbles alone on the vasculature
and their role in cancer therapy have been proposed
as an anti-vascular therapy (Wood et al. 2007; Goertz
et al. 2008, see Section IV). Thus, the relative
contributions of chemotherapeutics to the total observed
change needs to be determined.
In vitro studies.Ultrasound has been applied directly
to cell cultures in the presence of microbubbles and a
chemotherapeutic agent. When murine colon carcinoma
and murine mammary carcinoma cells were insonated
in the presence of cisplatin and microbubbles, apoptosis
was induced (Watanabe et al. 2008). Also, when head
and neck cancer cell lines were insonated in the presence
of microbubbles and cisplatin or cetuximab, Heath et al.
(2012) reported increased cancer cell permeability and
enhanced drug uptake and apoptosis. Sorace et al.
(2012) insonated a human breast cancer cell line in the
presence of microbubbles, a fluorescent dye (calcein)
and taxol, and found that maximum uptake of the extra-
cellular tracer occurred at 1.0 MHz and that cell death
was increased by 50% (compared with the controls).
They hypothesized that the microbubble-mediated ultra-
sound therapy increased cell membrane permeability
through the generation of small pores, which increased
passive intracellular delivery of taxol. Similarly,
increased membrane permeability was observed by
Yang et al. (2014) after insonation of a human myeloge-
nous leukemia cell line in the presence of doxorubicin
and microbubbles. The enhanced delivery of the chemo-
therapeutic agent resulted in cytotoxicity, cellular necro-
sis and DNA damage. Their findings supported those of
an earlier study by Escoffre et al. (2011), who had
reported an increased incidence of apoptosis in human
glioblastoma and breast cancer cells after insonation in
the presence of doxorubicin and microbubbles.
In vivo studies. A reduction in tumor size has been
reported with insonation after the chemotherapeutic
agent and microbubbles were either injected directly
into the tumor or administered intravenously. Cisplatin
(cis-diamminedichloroplatinum II) and microbubbles
were directly injected into human colon carcinoma cells
implanted subcutaneously in mice (Watanabe et al.2008). The tumor was then insonated, and a consequent
reduction in tumor volume was observed. Similar studies
of a subcutaneous murine melanoma were performed by
Matsuo et al. (2011) using melphalon as the chemothera-
peutic agent, and again, tumor regression was the result.
Lu et al. (2011) also made intratumoral (murine colon
cancer) injections of microbubbles before the intravenous
injection of epirubicin and tumor insonation. The authors
described retarded tumor growth and increased survival
times and reported that cavitation contributed to the tu-
mor growth inhibition. Intratumoral injections of micro-
bubbles may not, however, be suitable for clinical
practice as access to tumors may not be easy and a uni-
form distribution of the microbubbles throughout the
tumor parenchyma is often difficult to achieve. Observa-
tions of the insonation of a squamous cell carcinoma in
mice (Heath et al. 2012) after the intravenous injection
of cisplatin or cetuximab and a microbubble contrast
agent (Definity) revealed a reduction in tumor size,
apoptosis and increased cell membrane destruction. Hu-
man breast cancer cells were implanted subcutaneously
in the flanks of mice, and the resultant tumors were inso-
nated in the presence of intravenously injected microbub-
bles and taxol (Sorace et al. 2012). A pressure amplitude
of 0.5 MPa resulted in the highest impediment to tumor
growth over the 3-wk period and also produced the high-
est degree of tumor necrosis.
Role of microbubbles in opening blood–brain bar-
rier for cerebral chemotherapy. There is increasing
interest in the use of focused ultrasound in the presence
of circulating microbubbles to temporarily open the
blood–brain barrier (BBB). The barrier is characterized
by tight junctions between the endothelial cells lining the
blood vessels in the central nervous system so that the pas-
sage of nutrients into the brain via cellular pathways can be
closely regulated and brain homeostasis can be main-
tained. Further, the barrier also prevents toxic substances
as well as other pathogens from entering the brain. Tempo-
rarily increasing the permeability of the barrier will permit
the passage of chemotherapeutic agents into the neural tis-
sue, and it is this feature that is of particular relevance in
cancer therapy. The underlying bio-effect of insonation is
stable cavitation as energy is transferred to the circulating
microbubbles, causing them to expand and contract (oscil-
late) with resultant damage to the contiguous endothelial
cells and their tight junctions with resultant increases in
the permeability of the BBB. The topic has recently been
extensively reviewed by Burgess and Hynynen (2014)
and Liu et al. (2014). In Table 4, other recent publications
are listed together with the insonation parameters that were
used to increase the permeability of the barrier in normal
rodent brains and in those with implanted cerebral
neoplasms.
Table 4. Opening of blood–brain barrier with pulsed
focused ultrasound and microbubbles in rodents
Insonation parameter
ReferenceMHz W cm22 MPa
Normal brain 0.4 5.0–10.0 0.98–1.35 Liao et al. 2012b
— — 0.45–0.60 Chen et al. 2013b
1.5 — 0.45–0.60 Samiotaki and
Konofagou 2013
Implanted brain
tumor
Glioma 0.4 1.0–10.0 0.45–1.35 Liu et al. 2010
Breast cancer 0.69 0.32 0.69 Park et al. 2012
Glioma 1.0 — 0.7 Ting et al. 2012
Gliosarcoma 1.7 — 1.2 Treat et al. 2012
Glioma 0.69 — 0.55–0.81 Aryal et al. 2013
Glioma 0.40 4.0 0.325 Fan et al. 2013a
Glioma 1.0 3.0 0.6 Wei et al. 2013
Glioma 0.61 — 0.4 Kovacs et al. 2014
Astrocytoma
(unfocused US)
0.5 — 0.4 Kovacs et al 2014
US 5 ultrasound.
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imaging to reveal regions of breakdown of the BBB after
cerebral insonation in the presence of albumin-shelled
Gd-DTPA circulating microbubbles and found that a
threshold acoustic pressure of 0.98 MPa was required to
open the BBB. In further MR observations, Samiotaki
and Konofagou (2013) reported an opening threshold in
mice of 0.45 MPa in the presence of circulating Definity
microbubbles. A similar threshold was also found in mice
(Chen et al. 2013b) in which at 0.45 MPa there was a ho-
mogeneous breakdown of the BBB in the insonated hip-
pocampus in the presence of circulating microbubbles.
Additional observations with circulating phase-shift
nanodroplets (formed by pressurizing microbubbles so
that the gas core was converted into a liquid phase)
revealed that higher acoustic pressures were required to
open the BBB, but the incidence of inertial cavitation
was reduced (Chen et al. 2013b).
Further in vivo observations have been made in ro-
dents after chemotherapy of implanted brain neoplasms.
Liu et al. (2010) used MR imaging to follow tumor pro-
gression after opening of the BBB by focused sonication
in the presence of circulating microbubbles and treatment
with carmustine (bis-chloroethylnitrosourea). Tumor
growth was controlled, and animal survival times were
increased. In another study, carmustine was loaded onto
microbubbles, and brain insonation released the chemo-
therapeutic agent at the target site (Ting et al. 2012).
MR imaging revealed control of tumor progression, and
improved animal survival times were again observed. In
multiple investigations using doxorubicin (either alone
[Kovacs et al. 2014], encapsulated in liposomes [Aryal
et al. 2013; Treat et al. 2012] or conjugated with
supermagnetic iron oxide nanoparticles [Fan et al.2013a]), focused ultrasound therapy of a brain neoplasm
in the presence of microbubbles also resulted in reduced
tumor growth and an increase in median animal survival
times. These observations have also been confirmed using
other chemotherapeutic agents including trastuzumab
(Park et al. 2012; treatments given weekly for 6 wk)
and temozolomide (Wei et al. 2013). Burgess and
Hynynen (2014) have, however, raised the concern that
the intravenous drug concentrations selected for a suc-
cessful therapeutic outcome in the brain may have to be
adjusted to avoid potential peripheral toxicity.
It should, however, be noted that the normal BBB
is damaged by a brain neoplasm, and this is the reason
that iodine-containing contrast agents, in the case of
computed tomography, and paramagnetic contrast agents,
in the case of magnetic resonance imaging, can cross the
leaky barrier and reveal the cerebral pathology in each of
these imaging systems. Thus, the future clinical role of
ultrasound therapy may be to further increase the perme-
ability of an already leaky barrier and perhaps permit the
egress of larger chemotherapeutic molecules than is nor-
mally possible from the vascular lumen into the cancer
tissue.
Chemotherapy-loaded microbubbles and ultrasound
The chemotherapeutic drug may be loaded or bound
to a microbubble whose diameter is less than that of an
erythrocyte so that it easily enters the neovasculature of
a tumor (Liu et al. 2006b). On insonation of a tumor,
ultrasound targeted microbubble destruction occurs,
which has the advantages of being externally controlled
and localized to the tumor site. The formation of micro-
bubbles and their potential as carriers for drugs, small
molecules, nucleic acids and proteins have been reviewed
by Tinkov et al. (2009). The structure of the shell of mi-
crobubbles is important; lipophilic chemotherapeutic
drugs including doxorubicin, paclitaxel and docetaxel
can be incorporated into the lipid layer of a microbubble
(Kang and Yeh 2012). It is believed that such soft-shelled
microbubbles may be not be capable of stably incorpo-
rating large volumes of drug molecules because of their
relatively thin shells; the use of polymer-based
hard-shelled microbubbles permits the entrapment of
hydrophilic (rhodamine-B) and hydrophobic (coumar-
ine-6) chemotherapeutic agents in the shell and may
enhance the efficacy of cancer therapy (Fokong et al.
2012).
The concept of a theranostic microbubble which can
combine a chemotherapeutic role with ultrasound imag-
ing is receiving increased attention (Peyman et al.
2013; Zhao et al. 2013). The bubble is loaded with a
chemotherapeutic agent that is released into a tumor
under the action of low-intensity ultrasound; the bubbles
may also act as a contrast agent and be used for contrast-
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tumor vasculature. Stride and Coussios (2010) have pro-
vided an extensive review of the basic physics and cavi-
tation of microbubbles used in therapy and imaging and
how, when acoustically driven, they can be destroyed at
a tumor site and release a chemotherapeutic agent. The
mechanism underlying the delivery of a drug from the mi-
crobubble to a tumor was investigated using a light-
emitting compound loaded onto a microbubble (Liao
et al. 2012a). On insonation (1 MHz, pulsed, 3.0 W
cm22), the compound was released into tumor capillaries
and entered the neoplastic cells.
The incorporation of drugs onto the surface
of microbubble has been described (Ferrara et al. 2009;
Liu et al. 2006b; Mayer et al. 2008). During
tumor insonation, cavitation ruptures the bubble, thus
releasing the drug and delivering it into the tumor—it
may impart a ‘‘ballistic effect’’ to drive the drug through
thewall of the tumor capillary (Liu et al. 2006b).Also, son-
ication can oscillate the microbubbles, resulting in an in-
crease in the permeability of the contiguous cell
membranes, including those of the endothelial cells lining
tumor capillaries, and can further enhance the entry of a
locally released chemotherapeutic agent into a cancer cell
(Feril and Tachibana 2012; Stride and Coussios 2010;
Zhao et al. 2013). After insonation (1.5 MHz, pulsed, 1.0
W cm22) of a rat glioma cell culture, fibered confocal
fluorescence microscopy revealed in real time the
intracellular delivery of an impermeable green dye from
the microbubble into the cancer cell (Derieppe et al. 2013).
In vitro studies. Insonation, in the presence of micro-
bubbles, of a breast cancer cell line treated with
5-fluorouracil resulted in damage to the cells, and it
was presumed that the chemotherapeutic agent bound to
the albumin shell of the microbubble (Chumakova et al.
2006). Doxorubicin was embedded in the shell of the
microbubble, and its insonation in a culture of human
renal carcinoma cells resulted in enhanced cytotoxic
activity compared with that of free doxorubicin
and doxorubicin-loaded liposomes (Tinkov et al.
2010b). Yan et al. (2011) studied the bio-effects of
paclitaxel-loaded lipid microbubbles coated with a breast
tumor-homing peptide; the microbubbles attached to
human breast cancer cells, and insonation of the culture
resulted in reduced cell viability. Using a polymer micro-
bubble, Cochran et al. (2011) found that paclitaxel could
be loaded to a much greater extent than doxorubicin, and
on insonation of cultures containing loaded microbubbles
and human breast cancer cells, there was significant
release of paclitaxel, presumably as the microbubbles
ruptured, leading to the observed reduction in cell
viability. Ren et al. (2013) encapsulated docetaxel, a
hydrophilic molecule, in a lipid microbubble and foundthat insonation inhibited the proliferation of human colon
carcinoma cells.
In vivo studies. In power Doppler ultrasound images
of liver cancer in rabbits, Cochran et al. (2011) found that
doxorubicin-loaded microbubbles could permeate the
vasculature of the tumor. Their observation confir-
med the findings of Tinkov et al. (2010a), who used
doxorubicin-loaded microbubbles to treat a murine
pancreatic carcinoma that had been implanted subcutane-
ously in rats. After insonation, there was a reduction in
the tumor growth rate related to an increase in local
drug concentration. In comparison to the untreated con-
trols, a reduction in tumor growth rate, accompanied by
an increased survival time and reduction in the number
of metastases, was also reported in a liver tumor in rabbits
insonated after the intravenous injection of docetaxel-
loaded lipid microbubbles (Kang et al. 2010); ultrasound
therapy ruptured the microbubbles and released the drug
locally in the tumor tissues.
When 10-hydroxycamptothecin-loaded microbub-
bles were injected intravenously, they were also detect-
able in power Doppler images of a subcutaneously
located murine hepatic tumor (Li et al. 2012a). During in-
sonation of the tumor, the microbubbles fragmented into
nanoparticles, the fragments accumulated in the tumor
and the chemotherapeutic agent was slowly released.
The low blood flow in tumors and their large blood vol-
ume favored the infusion and destruction of microbubbles
within the tumor. Significant drug levels were delivered
locally, and the growth rate of the tumor was reduced;
there was, however, no reduction in the size of tumors
receiving unloaded microbubbles.Chemotherapy-loaded polymeric micelles or liposomes
and ultrasound
An alternative approach to loading a chemothera-
peutic agent onto a microbubble is to instead use a poly-
meric micelle or liposome. These micelles have been
used to improve the delivery of chemotherapeutic drugs
to a tumor; the aim is to release the agent from the micelle
under the action of ultrasound. The topic of ultrasound
activation of micelles has recently been reviewed
(Husseini and Pitt 2009; Rapoport 2012; Schroeder
et al. 2009b). It has been postulated that inertial
cavitation improves micelle delivery by creating holes
in the membranes of neoplastic cells so that the
micelles can diffuse into the neoplastic cells. Inertial
cavitation may also open the micelles to release the
now intracellular chemotherapeutic drug (Husseini and
Pitt 2009). It has also been suggested that the insonation
induces a mild hyperthermia that may enhance the move-
ment of the micelles from the tumor capillaries into the
interstitium of the tumor (Rapoport 2012).
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the effectiveness of the therapy method. Schroeder
et al. (2009a) reported that insonation of a colon adeno-
carcinoma implanted in the feet of mice after intravenous
injection of cisplatin-loaded liposomes inhibited tumor
growth, and the tumors regressed over time. In studies
of intraperitoneal or subcutaneous ovarian carcinomas
in mice, Gao et al. (2005) reported that ultrasound trig-
gered intracellular uptake of polymeric micelles encapsu-
lated with doxorubicin; the drug had previously been
injected intravenously and had accumulated in the inter-
stitium of the tumor. The growth rate of the subcutaneous
tumor also decreased. Further, Yan et al. (2013) intrave-
nously injected liposome–microbubble complexes con-
taining paclitaxel before insonation of mice with a
subcutaneous breast tumor. They reported an increase
in drug concentration in the tumor and inhibition of tumor
growth.
In a subcutaneous colorectal epithelial cancer cell
line in rats, Staples et al. (2010) reported that the infusion
of doxorubicin-labeled micelles and insonation (20 kHz,
continuous, 1.0 W cm22, and 476 kHz, pulsed, 23.61 W
cm22) led to higher concentrations of the chemothera-
peutic agent within the tumor for 30 min post-
insonation; at later times, similar levels of the agent
were present in insonated and non-insonated tissues.
The authors suggested that cavitation events may have
released the doxorubicin from circulating and extrava-
sated micelles into the tumor, and insonation could
have transiently increased the permeability of the tumor
neovasculature. With the progression of time, however,
cavitation could occur at slower rates as the micelles
are cleared from the circulatory system; also, the tumor
capillaries will regain their normal permeability, thus
explaining the similar levels of doxorubicin observed in
cancerous and normal tissues.
Rapoport et al. (2009) followed a different approach
in which nano-micelles loaded with paclitaxel or gemci-
tabine were infused into the tumor vasculature and
transformed by ultrasound into microbubbles after the
nano-emulsions had extravasated into the interstitium.
Ovarian, breast and pancreatic cancers were studied in
mice, and the results indicated enhanced delivery of the
chemotherapeutic agents to the tumors. There was also
a reduction in tumor growth; although the initial reduc-
tion was significant, subsequent treatments were less
effective, possibly because of the development of drug
resistance by the cancer cells.
To minimize the potential side effects a chemother-
apeutic agent on normal tissues, Ibsen et al. (2012) devel-
oped ‘‘shockwave ruptured nanopayload carriers’’ in
which a microbubble was encapsulated with a protective
outer liposome. Tissue phantom studies were performed
using 2.25 MHz ultrasound at the relatively higher pres-sure amplitude of 1.5 MPa. Insonation destroyed the
microbubble of perfluorocarbon gas and ruptured the
outer liposome membrane, and so had the potential to
release a highly concentrated chemotherapeutic payload
from within the particle.
Chemotherapy-loaded liposomes in the presence of
microbubbles and ultrasound
Inertial cavitation induced by the insonation of
microbubbles can augment the intracellular absorption
of a chemotherapeutic agent. Zhao et al. (2012) insonated
breast cancer cells in the presence of microbubbles and
doxorubicin-loaded liposomes; they reported that ultra-
sound mediated cavitation lead to the observed reduction
in cell viability in the treated cell cultures. In an in vivo
study, Lin et al. (2012a) used polyethylene glycol-
coated liposomes loaded with doxorubicin to treat a
murine colorectal adenocarcinoma implanted subcutane-
ously in mice. Microbubbles were injected intravenously,
and the tumor was insonated at a pressure amplitude of
1.2 MPa, before injection of the chemotherapeutic agent.
After therapy, there were significantly enhanced drug
levels in the tumor and delayed tumor growth. Also, it
was found in other experiments that the temperature of
the tumor increased by 5.0C when insonation occurred
in the presence of circulating microbubbles, but by only
2.5C in their absence. It was concluded that the absorp-
tion of ultrasound energy was enhanced by the oscillation
and cavitation of microbubbles within the insonated tu-
mor. Zhao et al. (2012) used an intratumoral injection
of microbubbles and an intravenous injection of
doxorubicin-loaded liposomes and found that the growth
of breast cancer tumors in mice was reduced when inso-
nated. It was also concluded that cavitation was an impor-
tant bio-effect of insonation and enhanced the absorption
of doxorubicin.
Chemotherapy-loaded liposomes attached to
microbubbles and ultrasound
The feasibility of the targeted delivery of a theranos-
tic agent under image guidance is addressed by the attach-
ment of drug-loaded liposomes to a microbubble of
ultrasound contrast medium. Diagnostic ultrasound can
be used to confirm the presence of the loaded microbub-
bles within the tumor vasculature; the application of low-
intensity ultrasound then ruptures the bubbles, accurately
restricting the delivery of the chemotherapeutic agent to
the neoplastic cells.
The cytotoxicity of doxorubicin-containing lipo-
somes coupled to the surface of microbubbles has been
illustrated in vitro. Lentacker et al. (2010), using mela-
noma cells, described an almost instantaneous cellular
entry of the chemotherapeutic agent after insonation,
which was thought to be related to sonoporation of cell
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cells, Geers et al. (2011) reported that 600–1300
doxorubicin-loaded liposomes were attached to the sur-
face of each microbubble, and insonation increased the
killing of the cancer cells. In another study of glioblas-
toma cells, insonated in the presence of similar liposomes
linked to microbubbles, Escoffre et al. (2013) reported a
decrease in cancer cell viability.
The therapeutic potential of combining drug-loaded
liposomes, microbubbles and ultrasound was observed by
Rapoport et al. (2007) when polyethylene glycol-coated
liposomes loaded with doxorubicin and perfluoropentane
microbubbles were used to treat breast cancer tumors
in mice. After intravenous injection of the liposome/
microbubble mixture and subsequent insonation, in-
creased uptake of doxorubicin into the tumor was
observed. The uptake of the drug was greater when mi-
crobubbles and drug-loaded liposomes were used than
when the liposomes were administered alone. The
observed increase was attributed to inertial cavitation.
Heating of tissue to 41C was also observed in normal
mice by Cool et al. (2013) when indocyanine green-
containing liposomes were coupled to the surface of
intravenously injected microbubbles; insonation
(1 MHz, 2.0–5.0 W cm22) caused release of the dye,
and it was concluded that the technique may have appli-
cations in improving ultrasound-mediated drug delivery.
An alternative approach has been reviewed by Ibsen
et al. (2013) in which the chemotherapeutic agent is car-
ried on the surface of the microbubble, and the loaded mi-
crobubble is in turn encapsulated within a liposome.
Potential advantages include the rapid release of the
encapsulated chemotherapeutic drug within the tumor
and a low leak rate of the agent into normal tissues.
The microbubble can also be used as an imaging contrast
agent, that is, theranostic agent, as it is involved in both
therapy and diagnosis.Chemotherapy in the presence of ultrasound and
magnetic nanoparticles loaded onto microbubbles
(magnetic microbubbles)
The encapsulation of iron oxide nanoparticles into
microbubbles enabled the development of multimodality
imaging, that is, (MR imaging in addition to ultrasound
imaging; the topic has recently been briefly reviewed
(Owen et al. 2012; Zhao et al. 2013). Niu et al. (2013)
developed such a multifunctional theranostic agent in
which pelvic limb lymph node metastases from an im-
planted squamous cell carcinoma in rabbits were imaged
by both MR and ultrasound. Doxorubicin and iron oxide
nanoparticles were co-encapsulated into microbubbles,
and insonation of the nodes triggered release of the
chemotherapeutic agent. The therapy increased apoptosisand decreased tumor proliferation andmicro-blood vessel
and lymphatic density.
Additional comments
In summary, investigations of ultrasound-mediated
chemotherapy have evaluated the efficiency of the deliv-
ery of a wide range of chemotherapeutic agents to cancer
cell cultures and suspensions and solid tumors. Across all
delivery methods, consistent findings have been a poten-
tiation of the efficacy of the delivery of chemotherapeutic
agents with resultant necrosis of neoplastic cells, inhibi-
tion of tumor growth and increased animal survival times.
The precise mechanisms underlying ultrasound-mediated
chemotherapy are, however, frequently based on specula-
tion rather than direct evidence. The insonation of a solid
tumor with low-intensity ultrasound in the presence of
an intravascular chemotherapeutic agent can potentiate
and localize the cytotoxic affects to the cancer cells,
while minimizing side effects in the adjacent normal
tissue. Traditional chemotherapy is given in low doses
over time, and future studies may determine whether
ultrasound-mediated chemotherapy can substantially
reduce the overall dose of the agent and decrease its
toxicity. Although some in vivo experimental studies
have used intratumoral or intraperitoneal injections of
the chemotherapeutic agent or microbubbles, intravenous
injections should result in a more even and generalized
distribution of these substances within the tumor and an
improved response to therapy.
Although large numbers of studies have reported the
efficacy of ultrasound-mediated chemotherapy, relatively
few have dealt with the issue of the biodistribution of the
agents and their elimination from the body. Those chemo-
therapeutic agent-loaded microbubbles not destroyed by
an ultrasound beam that has been localized to a tumor
will continue to circulate in the vascular system and
may be retained in amajor organ. Toft et al. (2006) studied
the biodistribution of the perfluorobutane gas contained in
amicrobubble at different time points after its intravenous
injection into rats. They observed that the highest concen-
tration of perfluorobutane was in the spleen, followed by
decreasing levels respectively in the liver, lung, kidney
and other tissues. They also reported that 50% of the per-
fluorobutane was recorded in the exhaled air by 20 min
after injection, and 96% was recovered in 24 h. Retention
of microbubbles in the sinusoidal spaces within the liver
has been reported, and they are phagocytosed by Kupffer
cells (liver-specific macrophages) (Cosgrove 2006; Liu
et al. 2008a; Yanagisawa et al. 2007). In in vitro studies,
acoustic pressures of 0.63 MPa were required to
destroy microbubbles adherent to Kupffer cells, and
0.73 MPa destroyed those microbubbles that had been
phagocytosed (Liu et al. 2008a). Microbubbles are also
taken up by the spleen, where they may be phagocytosed
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renchyma (Lim et al. 2004). Further, it has been reported
that lipid-shelled microbubbles are retained in the renal
cortex of mice and humans (Liu et al. 2013b). The micro-
bubbles were located in the murine glomerular microves-
sels after a complement-mediated interaction with the
vascular endothelium.
Given that the majority of the microbubbles are
destroyed during insonation of the tumor neovasculature,
it is likely that non-clinically significant levels of the
chemotherapeutic agent will be retained in the liver,
spleen or kidney. In considering future developments in
ultrasound-mediated chemotherapy, it will be important,
however, to fully understand the behavior and eventual
outcome of these phagocytosed or adherent microbub-
bles, especially as their associated chemotherapeutic
agent has the potential to cause toxic side effects in these
major organs.
Whether by diagnostic ultrasound or by MR imag-
ing, the ability to image the distribution of the chemother-
apeutic agent within the tumor has significant clinical
implications. By loading the chemotherapeutic agent
onto the surface of a microbubble of ultrasound contrast
medium, localized insonation of such a theranostic agent
could lead to accurate delivery of the drug to a tumor and
minimization of unwanted cytotoxic effects in the adja-
cent normal tissues. Further, it may be feasible to reduce
the systemic dose of the chemotherapeutic agent, leading
to a reduction in clinical side effects. In considering the
underlying bio-effects of such theranostic methods, the
emphasis has been placed on the role of inertial cavita-
tion; little attention has been given, however, to other
possible mechanisms including accompanying thermal
effects on the tumor vasculature. As the in vivo studies
have usually been performed in rat and mouse tumor
models, there is a need to progress to investigations in
naturally occurring neoplasms which could then lead to
initial clinical trials.ULTRASOUND-MEDIATED GENE
TRANSFECTION
Recently there has been considerable interest in the
emerging area of using ultrasound and microbubbles to
facilitate gene delivery to neoplastic cells (Feril et al.
2006; Geis et al. 2012; Liang et al. 2010; Sirsi and
Borden 2012). It has been hypothesized that the use of
focused ultrasound to target DNA-loaded microbubbles
located within the lumen of a tumor’s neovasculature
can result in destruction of the microbubbles and release
or transfection of genetic material locally into the tumor
parenchyma. It is further proposed that insonation also
causes the process of sonoporation in which transient
pores form in the cancer cell membranes through whichmolecules are able to enter the cell (Haag et al. 2006;
Li et al. 2014). In each case, insonation is considered to
be the driving force responsible for transfection of the
nucleic acids and the subsequently observed therapeutic
effects in the cancer cells. It remains uncertain,
however, as to exactly how genes pass through the
endothelial barrier to reach the tumor. Sporadic
capillary rupture and increased vascular permeability,
as well as enhanced permeability of cell membranes,
may play a role in the observed efficacy of therapy.
Some of the more recent studies are listed in Table 5;
the acoustic pressures required to promote gene transfec-
tion are usually greater than 0.3 MPa and so fall into a
general classification of moderate ultrasound intensities.
We have provided an introductory, preliminary review
of the topic, and the reader is encouraged to evaluate
the results of new investigations as further data
accumulate.
As a routine, gene therapy was easily targeted to a
tumor, and the investigations revealed successful trans-
fection of genetic material resulting in apoptosis of can-
cer cells, both in vitro and in vivo, and reduced tumor
growth. After insonation, the wide distribution of trans-
fection within the tumor led to a more efficient therapeu-
tic response; Fujii et al. (2013) were unable to detect
transfection in organs outside ultrasound beams. Micro-
bubbles loaded with genes or inhibiting RNA (directed
to epidermal growth factor) have been found to effec-
tively reduce tumor growth (Carson et al. 2011, 2012).
The underlying hypothesis is delivery of genes that
inhibit signaling processes to specific sites in the tumor
while sparing non-targeted areas. By this approach, selec-
tive payloads of these materials can be delivered non-
invasively and repeatedly.
On some occasions, the genetic material and micro-
bubbles were injected separately into a tumor (Tang et al.
2012), or alternatively, they were mixed and then added to
the tissue culture or injected into the tumor (Li et al.
2012b, 2014; Sakakima et al. 2005; Yamaguchi et al.
2011a; Zhang et al. 2011; Zolochevska et al. 2011). An
improved distribution throughout the parenchyma of
the tumor would, however, be expected when the
nucleotide and microbubble are linked and injected
intravenously. As the phosphate backbone of DNA and
RNA is highly anionic, microbubbles with cationic
shells have been used so that there is spontaneous
formation by electrostatic binding of a complex based
on the charge interactions (Wang et al. 2012a; Yu et al.
2013). In using such complexes, Wang et al. (2012a) re-
ported significantly enhanced transfection in both cell
cultures and tumors. They observed that the enhancement
in transfection efficiency with cationic microbubbles was
more pronounced in cell culture studies than in tumors.
Possibly more DNA was delivered in tissue cultures
Table 5. Insonation parameters used for ultrasound- and microbubble-mediated gene delivery
Cells/tumor
Insonation parameter
Treatment ReferenceMHz W cm22 MI MPa PW/CW
In vitro
Hepatocellular carcinoma 1.0 0.5 — — PW Interferon b Sakakima et al. 2005
Prostate 1.75 — 1.9 1.44* PW Anti-sense oligodeoxynucleotide Haag et al. 2006
Hepatoma 1.0 1.0 — — PW pEGFP Zhang et al. 2011
Prostate 0.021 4.6 — — PW pEGFP DNA Bai et al. 2012b
Endothelial cell 1.0 2.0 — — PW Click beetle luciferase Wang et al. 2012a
Breast cancer 2.0 0.75 — — CW KDRP-CD/TK Li et al. 2012b
Ovarian 1.0 0.5 — — PW PEGFP-N1-wtp53 Chang et al. 2013
In vivo
Hepatocellular carcinoma 1.0 2.0 — — PW Interferon b Sakakima et al. 2005
Prostate — — 1.9 — PW Anti-sense oligodeoxynucleotide Haag et al. 2006
Hepatoma 1.0 2.0 — — PW HSV-TK Zhou et al. 2010
Squamous cell carcinoma 1.3 — 1.6 1.40* PW TK Carson et al. 2011
Melanoma 1.011 0.22 — — PW Interferon b Yamaguchi et al. 2011a
Prostate 1.0 1.0 — 0.12 PW Interleukin-27 Zolochevska et al. 2011
Squamous cell carcinoma 1.3 — 1.6 1.40* PW sIRNA Carson et al. 2012
Nephroblastoma 1.0 1.0 — — CW DNA Sirsi et al. 2012
Hepatic 1.0 3.0 — — PW KDR-TK, AFP-TK Tang et al. 2012
Endothelial cell 1.0 2.0 — — PW Click beetle luciferase Wang et al. 2012a
Mammary adenocarcinoma 1.3 — — 2.1 PW shRNA Fujii et al. 2013
Hepatoma 1.3 — 1.3 1.14* PW HSV-TK/GCV Yu et al. 2013
Renal carcinoma 1.0 2.0 — — PW Recombinant adeno-associated virus Li et al. 2014
CW 5 continuous wave; MI 5 mechanical index; PW 5 pulsed wave; — 5 parameter not available.
* Represents calculated negative peak pressure 5 MI  ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃfrequencyp .
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be the extent of cavitation activity: there may have been
more cavitation in vitro than in vivo.
In these ultrasound-mediated methods, the transfec-
tion/transduction of genetic material was usually accom-
plished using non-viral techniques, but use of a virus as a
carrier with microbubbles was also successful (Li et al.
2014; Tang et al. 2012). Compared with viral vectors,
non-viral techniques have increased tolerability, but are
disadvantaged by low transfection efficiencies (Wang
et al. 2012a); however, microbubbles are good carriers
of genes with a greater capacity for anti-sense oligonucle-
otides and fragments of DNA and even the entire chromo-
some (Li et al. 2012b).
As far as the underlying bio-effects are concerned,
during insonation, the in vivo cavitation activity is
confined to microbubbles within the lumens of the tumor
neovasculature, and it remains to be elucidated how
these cavitation events induce sonoporation and vesicle
formation in the extravascularly located cancer cells. In
summary, ultrasound-mediated gene therapy is non-
invasive, and repeated delivery can be used to achieve a
more sustained transfection; also, multiple genes can be
delivered to achieve a synergistic therapeutic response
(Fujii et al. 2013). The method is site specific, thus
providing a distinct advantage over systemic cancer
therapies for tumors with their associated effects on
normal tissues (Carson et al. 2012; Sirsi et al. 2012). It
should, however, be remembered that after insonation,
the transfection of genes could result in unexpectedmorphologies and abnormalities in normal cells
contiguous with the tumor. In the future, animal
investigations could be aimed at following tumors over
longer periods post-therapy and making repeated deliv-
eries of genetic material. Also, a multigene approach us-
ing a combination of anti-angiogenic and pro-apoptotic
gene therapies could be useful (Fujii et al. 2013).ANTI-VASCULAR ULTRASOUND
It has been proposed that a solid tumor should be
considered to have two compartments of cells, one con-
taining the neoplastic cells and the other the endothelial
cells of the tumor neovasculature (Folkman 2001;
Siemann 2006). As a solid tumor exceeds a cubic
millimeter in volume, it must establish its own vascular
supply to ensure the continuing viability of its cancer
cells. It is well established that the tumor neo-
vasculature differs in structure from that of normal
blood vessels: tumor vessels are fragile and leaky and
have abnormal branching patterns (Vaupel 2006).
Ultrasound imaging using circulating microbubbles
has become the method of choice to visualize the tumor
neovasculature and to differentiate between vascular
and avascular regions within a tumor (Anderson et al.
2011; Chen et al. 2013c; Hyvelin et al. 2013; Perini
et al. 2008; Wood et al. 2005, 2006). The technique can
also be used to assess the efficacy of an anti-vascular ther-
apy. After the intravenous injection of microbubbles, the
vascular regions within a tumor can be identified in
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aging [Sehgal et al. 2009]) and power Doppler images
(visual inspection, percentage area of flow and color
weighted flow area, cumulative histogram area [Mason
et al. 2011; Wood et al. 2007]). Alternative approaches
using high-frequency Doppler imaging without the use
of microbubbles have also been developed. Goertz et al.
(2002) and Chen et al. (2011, 2012a) observed the
vascularity of murine tumors in power Doppler images
made at 25–38 MHz, and in a study of a prostatic
adenocarcinoma implanted in mice, Chen et al. (2013b)
assessed vascular perfusion at 25 MHz in power Doppler
images by measuring the ratio of the color weighted
pixels to the total tumor area or percentage area of flow.
This review centers on techniques using the combi-
nation of ultrasound and microbubbles as a vascular dis-
rupting agent (Fig. 3); the tumor vasculature is damaged,
leading to necrosis of the neoplastic cells with a conse-
quent reduction in tumor growth and lengthened survival
time. Although this review is focused on the role of low-
intensity ultrasound as part of such an anti-vascular tumor
therapy, we have also included references to the use of
moderately higher intensity insonations (Table 6). The
anti-vascular responses to these differing approaches
are probably related to major differences in their bio-
effects: lower intensities are reported to create more ther-
mal effects, and higher intensities, more cavitation ef-
fects. Such divisions, however, may be considered
artificial as the two effects are intertwined, and seldom
is it true that one class of effects can be disregarded
(Baker et al. 2001).
Predominantly thermal bio-effects
In multiple studies of a murine melanoma model, it
was consistently found that tumor insonation (1- to 3-min
treatment time) in the presence of circulating microbub-
bles had a significant anti-vascular effect (Wood et al.Fig. 3. Schema of anti-vascular ultrasound. Microbubbles cont
low-intensity ultrasound, causing a series of bio-effects that lead
and, consequently, necrosis and apoptosis of cancer cells occu
microbubb2005, 2006, 2007, 2008, 2010). Each minute of
insonation decreased tumor perfusion by z25% (Wood
et al. 2005). Of particular interest in these theranostic
studies was the observation that the normal vasculature
in the adjacent tissues and organs appeared unaffected
by the therapy. The tumor increased in echogenicity after
therapy; it appeared to be related at least in part to tissue
inhomogeneities formed after disruption of the tumor
neovasculature (Wood et al. 2009). In detailed histologic
observations, the predominant effect of insonation was an
irreparable dilation of the tumor capillaries with associ-
ated intercellular edema (Bunte et al. 2006). There were
also hemorrhage and increased intercellular fluid. A day
after insonation, liquefactive necrosis of the neoplastic
cells had occurred and was related to a generalized tumor
ischemia following the effects of therapy on the neo-
plasm’s vascular channels. It should be noted that this
histologic finding differs from that reported after tumor
insonation with high-intensity focused ultrasound, where
acute coagulative necrosis occurs, not only of the
neoplastic cells, but also of the tumor vasculature (Van
Leenders et al. 2000; Wu et al. 2001, 2002). These
observed bio-effects resulted in reduced tumor growth
rate and a 28% increase in survival time after a single
3-min tumor therapy session (Wood et al. 2010). The
anti-vascular action of low-intensity ultrasound was
increased when tumor insonation was at 3 MHz rather
than 1 MHz, and the temperature of the tumor increased
by 5C and 2C min21, respectively (Wood et al. 2008).
Thus, it was considered that a thermal effect on the endo-
thelial cells lining the tumor capillaries may be important,
although other bio-effects, sonochemical reactions and
cellular responses could also play a role (Wood et al.
2005, 2008). In recent studies, Hunt et al. (2014) found
that the effects of anti-vascular ultrasound go beyond
direct cytotoxicity to include intratumoral immune
activation.ained in the neovasculature of a tumor are insonated with
to vascular damage. Blood flow to the tumor is disrupted
r. EC 5 endothelial cell; US 5 ultrasound; m-bubbles 5
les.
Table 6. Anti-vascular ultrasound therapy of tumors in the presence of circulating microbubbles
Type of microbubble Tumor
Insonation parameter
ReferenceMHz W cm22 PW/CW MPa
Unloaded Melanoma 1.0–3.0 2.0 CW 0.28 Wood et al. 2005, 2006, 2007, 2008, 2010
Three tumor types 1.0 — PW 0.74 Goertz et al. 2008, 2009
Adenocarcinoma 1.2 — PW 5.0 Chin et al. 2009
Colon carcinoma 1.5 133* — — Zhong et al. 2010
Glioma 1.0 — PW 1.0–1.2 Burke et al. 2011
Adenocarcinoma 1.0 2.0 PW — Lin et al. 2012a
Walker-256 0.83 0.4, 1.36 PW 2.6, 4.8 Liu et al. 2012
Colon carcinoma 0.24 — PW 0.5 Huang et al. 2013
Hepatoma 1.75 539 — — Wang et al. 2013a
Breast cancer 5.0 — PW 4.0 Hu et al. 2012
Epidermoid 1.22 0.89 PW 4.6 Peijing et al. 2014
Unloaded 1 anti-angiogenic genes Prostate 1.0 2.0 PW — Duvshani-Eshet et al. 2007
Hepatoma 1.0 2.0 PW — Nie et al. 2008
Loaded
Docetaxel Squamous carcinoma 0.3 2.0 — — Kang et al. 2010
Docetaxel Prostate 1.0 — PW 1.65 Goertz et al. 2012
Doxorubicin Breast cancer 3.0 2.0 PW — Rapoport et al. 2007
Doxorubicin Colorectal 1.0 2.0 PW 0.6 Lin et al. 2012b
Carmestine 1 anti-angiogenic
complex
Glioma 1.0 — PW 0.5 Fan et al. 2013b
Anti-angiogenic agent Colon cancer 0.24 — PW 0.5 Zhang et al. 2014
CW 5 continuous wave; PW 5 pulsed wave; — 5 details not provided.
* Estimated.
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(2012) considered the tissue as a continuum of
microbubble-filled vasculature, cells and interstitial
fluids with compressibility equal to the sum of the
compressibilities of each component. The mathematical
simulations established that the absorption of ultrasound
by viscous dampening of the microbubble oscilla-
tions induced local heating of the neovasculature.
Microbubble-enhanced heating was also modeled and
observed in a phantom by Razansky et al. (2006). Blood
flow is slower in tumor neovasculature than in the
normal vasculature of healthy tissues, and thus, in tu-
mors there is additional time for an interaction between
ultrasound and microbubbles with resultant thermally
induced damage to endothelial cell linings, leading to
the observed anti-vascular effect of therapy (Levenback
et al. 2012). Such damage will be significantly dimin-
ished in normal capillaries where the circulation is faster
and any temperature rise will be much smaller and have
no biological effect.
In a study of normal rabbits, McDannold et al.
(2006) insonated the brain using 1.5-MHz focused,
continuous and pulsed ultrasound in the presence of
circulating microbubbles. Small focal regions (1 mm in
diameter) were sonicated at intensities significantly
.5.0 W cm22. Magnetic resonance observations re-
vealed temperature increases in the brain after insonation
that had caused necrosis of the entire sonicated area
following interruption of the vascular supply.In a further simulation of tissue heating by micro-
bubbles at 1 mW cm22, Umemura et al. (2005) found
that the increased absorption of ultrasound was primarily
at the resonance frequency; with ultrasonic intensities of
1 W cm22, increased absorption occurred at both reso-
nance and subharmonic frequencies. At intensities
greater than 1 W cm22, ultrasound absorption was
observed at two or three broadband resonance peaks.
They concluded that microbubble-enhanced absorption
doubled at microbubble concentrations as low as 8 bub-
bles mm23. In vivo experiments in rat kidneys at high
spatial peak intensities up to 290 W cm22 in the focal
range increased temperature by three to five times and
caused coagulative necrosis of the tissue. In another
study, Klotz et al. (2010) modeled microbubble oscilla-
tions in a simulated microvascular network of the rat
brain using focused ultrasound. The Pennes bioheat trans-
fer equation was used to calculate the heat absorbed dur-
ing the microbubble oscillations, and Klotz et al. reported
that the temperature increased most around the bubbles
and, to lesser extent, throughout the tissues. In the pres-
ence of 107 microbubbles mL21, the ideal insonation
parameters were found to be 1.5MHz and pressure ampli-
tudes of 0.8–1.4 MPa.
Predominantly cavitation bio-effects
In a review of in vitro observations of the effects of
insonation of cancer cells in the presence of microbub-
bles, Bai et al. (2012a) concluded that microbubble
920 Ultrasound in Medicine and Biology Volume 41, Number 4, 2015heating at ,0.2 MPa may be related to stable cavitation;
at higher acoustic pressures.0.6 MPa, inertial cavitation
becomes important. Use of a low-intensity insonation in
the presence of microbubbles similar to that used by
Wood et al. (2007, 2008), Lin et al. (2012a) found in
rabbits that the growth of colorectal adenocarcinoma
was inhibited; however, they hypothesized that during
insonation, oscillation of the microbubble and its
collapse with violent cavitation may disrupt the walls of
the tumor neovasculature and so delay tumor growth.
Intravascular inertial cavitation was observed in
rabbit ears by Tu et al. (2006) using focused ultrasound
at 1.17 MHz and peak rarefaction pressures of 1–9 MPa
(estimated intensity 5 40–1,000 W cm22). Other
in vivo studies of tumor models have centered on the
anti-vascular actions of pulsed ultrasound beams at
higher intensities and pressure amplitudes where the pre-
dominant effect on circulating microbubbles has been in-
ertial cavitation. Using pulsed ultrasound, Goertz et al.
(2008, 2009) insonated various murine tumors after the
intravenous injection of microbubbles and found a
reduction in tumor blood flow; when weekly treatments
were given, the growth of the tumor was inhibited
(Goertz et al. 2009). They reported that the signals
emitted from the microbubbles during tumor insonation
were consistent with the occurrence of inertial cavitation
(Goertz et al. 2009). Cavitation was also considered to be
the bio-effect leading to reduced tumor growth, tumor
necrosis and decreased expression of an angiogenesis
marker (CD31) (Huang et al. 2013).
Zhong et al. (2010) observed that ultrasound at a
high mechanical index of 1.7 (an estimated intensity
of 133W cm22) and microbubbles inhibited hepatic me-
tastases from a colon carcinoma in the spleen of rats.
The metastases were smaller in number and size. Histol-
ogy of the spleen revealed a decrease in the number of
tumor cells, hemorrhage and necrosis. It was concluded
that cavitation had damaged the capillaries, activated
coagulation systems and induced thromboses leading
to avascular regions and blockage of metastatic
channels.
Using higher peak intensities (2.6 and 4.8 MPa), Liu
et al. (2012) insonated a rat tumor after intravenous injec-
tion of microbubbles and described disruption of the
tumor microvasculature. Therapy was accompanied by
decreases in tumor temperature and tumor mean gray
scale. It was believed that the vascular effects were due
to cavitation; these findings were supported by additional
observations by Peijing et al. (2014) in a rabbit tumor.
Ultrasound at 4.3 MPa in combination with microbubbles
enhanced liver ethanol ablation in rabbits and was accom-
panied by temporary interruption of perfusion (Liu et al.
2013a). Wang et al. (2013a) investigated the effect of
focused ultrasound (mechanical index of 0.1–0.3,ISPTA5 539 mW cm
22) and microbubbles on the perme-
ability of the capillaries of a rat hepatoma; Evans blue
was the marker of vascular permeability. They suggested
that the treatment regimen could induce intravascu-
lar cavitation, thus increasing the permeability of
the neovasculature; higher-mechanical-index sonications
caused more cavitation and induced greater vascular
permeability.
Role of other bio-effects, chemotherapeutic and anti-
angiogenic agents and anti-angiogenic genes
Other bio-effects of therapy have also been consid-
ered. After repeated daily treatments (over about 12 d)
of a mouse colon adenocarcinoma in the presence of
circulating microbubbles, Chin et al. (2009) found that
the tumors were smaller and insonation caused no sig-
nificant temperature increases. They hypothesized that
it was unlikely that tumor cells or vascular endothelium
was destroyed acutely during treatment, as tumor blood
flow was restored after each therapy. They attributed the
reduced tumor growth to an inflammatory response. Af-
ter the intravenous injection of microbubbles, Burke
et al. (2011) insonated (treatment time5 1 h) C6 rat gli-
oma tumors implanted subcutaneously in mice using
very short duty cycles (0.00002–0.01 s). A week after
therapy, tumor necrosis and tumor growth inhibition
were greatest where the longest duty cycles were used
and the temperature of the tumor also increased post-
therapy (an increase of 5.4C at a duty cycle of 0.01
s). It was hypothesized that mechanical bio-effects
were more important than thermal effects in the anti-
vascular actions.
In another study of the breast cancer cell model in
mice, microbubbles conjugated with peptides were in-
jected and bound to tumor endothelial cell receptors
(Hu et al. 2012). Insonation resulted in reduced tumor
blood flow, which returned to normal within 30 min. It
was hypothesized that platelet activation was the likely
mechanism for flow reduction in the neovasculature.
It was reported by Goertz et al. (2012) that anti-
vascular action is enhanced by using the chemothera-
peutic agent docetaxel at a higher pressure amplitude
(1.65 MPa), and it was believed that inertial cavitation
was the major source of the anti-vascular effects. By
labeling a drug-loaded (carmustine) microbubble with
an antigen to vascular endothelial growth factor, Fan
et al. (2013b) enhanced delivery of the chemotherapeutic
agent to the tumor neovasculature. Use of the anti-
angiogenic complex was studied in a rat glioma model
in which the blood–brain barrier was broken down in
the presence of insonation and the circulating microbub-
bles. Local delivery of the chemotherapeutic agent was
enhanced with resultant suppression of the growth of
the glioma, and the animals’ survival time was increased.
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drugs in the presence of ultrasound and microbubbles
was also reported by Rapoport et al. (2007) (2.0 W
cm22), Burke and Price (2010) (undefined chemothera-
peutic agent and ultrasound intensities) and Lin et al.
(2012b) (0.6 MPa). Anti-tumor activity was also superior
when metronomic chemotherapy was combined with ul-
trasound and microbubbles at an ultrasound pressure
amplitude of 1.65 MPa (Todorova et al. 2013).
Zhang et al. (2014) conjugated an anti-angiogenic
drug (Endostar) with microbubbles and retro-orbitally in-
jected these into mice with a subcutaneous human colon
cancer before insonation (238 kHz, pulsed, 0.5 MPa).
They reported inhibition of tumor blood flow and delay
in tumor growth related to decreased expression of
vascular endothelial growth factor receptor 2 and avb-3
integrin.
In observations of a murine colorectal adenocarci-
noma, neoplastic cells were implanted in the ear (Lin
et al. 2012b). Polyethylene glycol-coated liposomes
loaded with doxorubicin were intravenously injected,
followed by intravenous microbubbles and insonation
(1.0 MHz, pulsed, 2.0 W cm22). Tumor growth was
significantly inhibited, and therapy was considered to
have disrupted tumor blood vessels and enhanced the
delivery of drug into tumor tissue; that is, the anti-
vascular effect trapped the doxorubicin in the tumor.
Because of the vascular damage within the tumor, Lin
et al. (2012b) raised the possibility that their treatment
may facilitate the release of neoplastic cells into the gen-
eral circulation, leading to metastatic disease. Kang et al.
(2010), however, found that although metastases from a
liver tumor in rabbits still occurred, their extent was
reduced after therapy with docetaxel-loaded microbub-
bles and ultrasound.
There is also interest in a primarily anti-vascular role
of gene therapy techniques. In a murine hepatocellular
carcinomamodel, Nie et al. (2008) intravenously injected
plasmid DNA with microbubbles and then insonated the
subcutaneous tumor. Transference of an anti-angiogenic
gene resulted in a significant anti-vascular effect with
reduced microvessel density and tumor growth. Unlike
the majority of studies in which microbubbles were in-
jected intravenously, Duvshani-Eshet et al. (2007) used
intratumoral injections of Optison to facilitate delivery
of an angiogenesis-inhibiting gene; the murine prostate
cancer was insonated at 2.0 W cm22, and tumor growth
was inhibited especially when weekly treatments were
given over 4 wk. Many anti-vascular effects are mediated
through effects on the endothelial cells of the tumor
neovasculature. In vitro culture studies by Al-Mahrouki
et al. (2012) indicated that microbubbles stimulated at
0.57 MPa upregulated the genes involved in apoptosis
pathways.Additional comments
The combination of the use of microbubbles for both
anti-vascular therapy and vascular imaging is an impor-
tant innovation, as such a theranostic agent exploits the
use of ultrasound imaging for monitoring the success of
anti-cancer therapy. Targeting the neovascular cell
compartment of a tumor with low-intensity ultrasound
in the presence of circulating microbubbles of ultrasound
contrast agent consistently resulted in loss of tumor
vascular perfusion. As a result, the neoplastic cell
compartment within the avascular regions underwent
liquefactive necrosis with a resultant decrease in tumor
volume and an increase in survival times of the laboratory
animals. The velocity of blood flow in the tumor neovas-
culature is slower than that in the vessels of the normal
contiguous tissues, thus explaining why the bio-effects
resulting from the interaction between ultrasound and a
microbubble are so much greater within a neoplasm and
why the circulation of the adjacent normal tissues appears
unaffected. Thus, the therapy technique accurately targets
the neovasculature of the tumor while sparing the normal
blood vessels in the adjacent healthy tissues.
In the anti-vascular treatment of a neoplasm it is
essential to deliver sufficient energy to the circulating
microbubbles within the lumens of the tumor neovascula-
ture. The microbubbles provide a mechanism for deliv-
ering the acoustic energy at sites contiguous with the
endothelial cells lining the neovasculature, resulting in
their disruption. Both thermal and cavitation effects
have been implicated as biophysical mechanisms of inter-
action. Those studies using continuous wave ultrasound
have emphasized thermal bio-effects, whereas the pulsed
ultrasound observations have emphasized cavitation. It is
difficult to separate the two effects. In all likelihood, both
effects are likely to play a role, although by varying the
nature of sonication conditions, one or the other mecha-
nism may dominate. For example, low intensities and
long tone bursts or continuous wave ultrasound may
emphasize microbubble oscillations for long intervals
and thus lead to significant heating effects. Higher inten-
sities with shorter pulses may, on the other hand, empha-
size bubble collapse and thus inertial cavitation. In
addition, other non-thermal effects including microshear
associated with microbubble oscillations, radiation pres-
sure and sonochemical reactions may also play a role,
although to date the evidence for these mechanisms is
limited.
Cancer cell death is a secondary effect of anti-
vascular ultrasound: it has both benefits and limitations.
The benefit is that the effect is generic and not specific
to any tumor type. Further, it does not require treatment
of individual cancer cells, because the survival of several
thousand cells depends on an individual blood vessel; dis-
rupting a few blood vessels could trigger cell death in
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access only to the surface of the endothelial cells, unlike
anti-vascular drugs that need to penetrate the cells to
affect their cytoskeleton. Also, compared with high-
intensity focused ultrasound, the anti-vascular ultrasound
instruments are likely to be less costly, simpler to design
and safer to use in clinical settings. In anti-vascular ultra-
sound, the insonating beam in unfocused, so that the
entire neoplasm can be treated directly without the need
to ‘‘paint’’ the lesion with successive small regions of
treatment. A limitation of anti-vascular ultrasound is
that susceptible tumor neovasculature has to be present
for the therapy to be effective.
Future studies could be aimed at further investi-
gating the potential for inciting an intratumoral immune
response (Hunt et al. 2014) and enhancing chemothera-
peutic retention. After anti-vascular ultrasound therapy
of murine melanomas, Hunt et al. (2014) described a
lymphocyte-mediated inflammation characterized by
the presence of T lymphocytes within the tumors, which
raises the possibility of the induction of a systemic post-
therapy immune response against the cancer cells. In
post-therapy MR observations of the melanomas, Hunt
et al. (2014) found that washout of the MR contrast agent,
gadolinium, was decreased and it was retained within the
tumor, thus supporting the work of Goertz et al. (2012)
and illustrating the potential role of anti-vascular ultra-
sound in trapping a simultaneously administered thera-
peutic agent within the tumor (Goertz et al. 2012).
The anti-vascular effects on the tumor neovascula-
ture are potent, but there remains, however, a need
for additional experiments to optimize the bio-effects;
the anti-vascular effects should be maximized while
continuing to minimize the collateral damage in the adja-
cent normal tissues. The differences in mechanisms of
interaction for different sonication intensities also need
to be investigated.CONCLUSIONS
Sonodynamic therapy, ultrasound-mediated chemo-
therapy and gene delivery and anti-vascular ultrasound
therapy, all of which use low-intensity ultrasound,
consistently produced bio-effects that resulted in the
death of cancer cells. Low-intensity applications of ultra-
sound are believed to be tolerable and non-toxic, can
easily be applied to a tumor and require relatively inex-
pensive equipment. It is probable that more than a single
bio-effect resulted in the efficacy of a therapy, although
the importance of thermal and inertial cavitation bio-
effects has been established in animal tumor models.
In some situations, the accessibility of the tumor to inso-
nation is a limitation as the cancer cells may be contig-
uous with a gas-containing structure or bone and noteasily reached by the ultrasound beam. In such clinical
situations, this limitation can be overcome by the use
of intracavity transducers for imaging and therapy.
Furthermore, the currently designed microbubbles have
a limited loading capacity to deliver therapeutic agents
at the required dosages. These limitations could be over-
come by an improved microbubble design so that they
can carry greater payloads. Co-administration of thera-
peutic agents along with the microbubbles could also
be exploited as a means to overcome the issue of suffi-
cient payload.
There is a generally held assumption that the agents
used with ultrasound and microbubbles are not them-
selves directly affected by the insonation. In the presence
of microbubble collapse and cavitation, sonochemical
effects of ultrasound may also occur (Verrall and
Sehgal 1988). Thus it remains to be learned whether
injected agents including chemotherapeutics, genes or
other sonosensitizers are not directly altered by ultra-
sound in the presence of microbubbles; the lack of any
significant direct insonation effect on these agents could
potentially accelerate their clinical acceptance and intro-
duction. Further, the underlying mechanisms of action
and transport of the agents from the tumor neovasculature
to their site of action in the extravascular space of the tu-
mor could be further explored. Finally, because the neo-
vasculature plays such a crucial role in delivery of the
agents, the in vitro cellular studies that are commonly per-
formed by direct insonation should also, in the future,
take into consideration the role of tumor neovasculature.
The use of microbubbles for both therapy and
vascular imaging is an important innovation, as such a
theranostic agent establishes a therapeutic–diagnostic
platform that can monitor the success of anti-cancer ther-
apy. The literature contains a large amount of data on the
effects of low-intensity ultrasound therapy on cancer cells
and mostly subcutaneously located tumor models in mice
and rats. Future animal cancer trials should include longi-
tudinal studies in which repeated treatments are given
over time, as these would mimic the likely clinical treat-
ment regimens. There is a paucity of data, however,
on the value of each of these therapies in naturally
occurring cancers and in larger mammals; if the results
of such future investigations were encouraging, they
could promptly be applied in a clinical trial.REFERENCES
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